Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice | Zendy

Lucie Poupel | Zendy; Alexandre Boissonnas | Zendy; Patricia Hermand | Zendy; Karim Dorgham | Zendy; Elodie Guyon | Zendy; Constance Auvynet | Zendy; Flora Saint Charles | Zendy; Philippe Lesnik | Zendy; Philippe Déterre | Zendy; Christophe Combadière | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Inhibition of the Chemokine Receptor, CX3CR1, Reduces Atherosclerosis in Mice

Author(s) -

Lucie Poupel,

Alexandre Boissonnas,

Patricia Hermand,

Karim Dorgham,

Elodie Guyon,

Constance Auvynet,

Flora Saint Charles,

Philippe Lesnik,

Philippe Déterre,

Christophe Combadière

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.300930

Subject(s) - cx3cr1 , monocyte , ccr2 , chemokine , in vivo , chemokine receptor , apolipoprotein e , medicine , inflammation , pharmacology , immunology , macrophage , cc chemokine receptors , receptor , endocrinology , biology , in vitro , disease , biochemistry , microbiology and biotechnology

Alterations of the chemokine receptor CX3CR1 gene were associated with a reduced risk of myocardial infarction in human and limited atherosclerosis in mice. In this study, we addressed whether CX3CR1 antagonists are potential therapeutic tools to limit acute and chronic inflammatory processes in atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research